| Value | ₹50.00 Cr |
|---|
BSE filing, NSE: BACPHAR. Summary written from the filing by ALFA Finder's alert engine.
Bacil Pharma Ltd: key numbers
- Share price
- ₹19.36
- Market cap
- ₹27.79 Cr
- Revenue (annual)
- ₹0.00 Cr
- Net profit (annual)
- ₹1.56 Cr
- P/E (TTM)
- 44.0×Sector 46.1×
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Bacil Pharma Ltd
All →Bacil Pharma Other Announcement
Bacil Pharma Ltd submitted its quarterly shareholding pattern for the period ending September 30, 2026, in compliance with SEBI Regulation 31.
Bacil Pharma Q2 FY27 Results: Net Loss of ₹0.1 Cr
Bacil Pharma Ltd reported a net loss of ₹0.1 Cr for Q2 FY27.
- Key figure
- Net loss ₹0.1 Cr
Bacil Pharma Management Change
Mr. Dikshant Singh Panwar has resigned as Whole-Time Company Secretary and Compliance Officer of Bacil Pharma Limited, effective October 8, 2026.
Bacil Pharma Board Meeting Date
Bacil Pharma will hold a board meeting on October 14, 2026, to consider and approve the unaudited financial results for the quarter and half-year ended September 30, 2026.
Bacil Pharma Annual Report
Bacil Pharma Limited submitted its 39th Annual Report for FY 2025-26. The Annual General Meeting is scheduled for September 23, 2026, via video conferencing.
Bacil Pharma Annual General Meeting
Bacil Pharma Limited has announced book closure dates from September 17 to September 23, 2026, for its 39th Annual General Meeting.
Other board meeting outcome announcements
All →R R Kabel Board Meeting Outcome
RR Kabel's board approved amendments to its UPSI fair disclosure code on 28 October 2026. The amended code is enclosed and posted on the company website.
M K Exim (India) Board Meeting Outcome
M.K. Exim (India) approved shifting its registered office within Jaipur to Plot J-1247, Sitapura. The board meeting was held on October 28, 2026.
United Spirits Board Meeting Outcome
United Spirits' board approved amendments to its insider trading code on 28 October 2026, effective 29 October 2026. The revised code is available on the company website.
SBI Funds Management Board Meeting Outcome
SBI Funds Management extended internal auditor Chhajed & Doshi's term to March 31, 2030. This routine decision was taken at the October 28, 2026 board meeting.
- Execution
- April 1, 2028 to March 31, 2030
Paras Healthcare Board Meeting Outcome
Paras Healthcare filed its board-approved UPSI fair disclosure code under Regulation 8(2). This routine governance policy update reports no business event.
Gateway Distriparks Board Meeting Outcome
Gateway Distriparks' board approved a revised Code of Practices for Fair Disclosure of UPSI under PIT Regulation 8(2). This is a routine governance policy update with no business event.